Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (895)	11/23/2005 6:06:28 PM
From: richardred	Read Replies (3) \| Respond to of 7256

I think it's a good gamble, at this point. If you hold, and if a hostile offer is upped and successful. Possibly more cash being offered, is in the PR. You also could be stuck with some MNT stock. Witch may, or may not, be a good thing. I find it amusing that Medicis is asking Inamed's board to rally shareholders to reject a higher offer from Allergan Inc. I find this point below key. This suggest to me Allergan is expecting Federal trade commission trouble. >Allergan has said it would immediately divest Inamed's Reloxin license to minimize any antitrust issues in its proposal to acquire Inamed. Ultimately, that might give Medicis a second shot at gaining access to Inamed's Botox-like product if its deal with Inamed collapses. "Medicis might just get everything they want and the $90 million break-up fee. We'll just have to see," Gunderson said. The possible risk I see here is. Medicis will up its offer to a much stronger cash rich Allergan. A fight I don't think Medicis can win. I expect it to take it's 90 million break up fee and run. I think Mentor is anticipating this also. The FTC could also stall this deal. Best case scenario -Allergan being a White knight buying both Inamed and Medicis. Worst case -Mentor backs off and stock most likely sinks back stightly above where it was trading before their interest. Good Luck >points in your court >Mentor said it expects the transaction to immediately boost cash earnings. Analysts surveyed by Thomson Financial expect earnings per share of $1.59 in 2006 and $1.98 in 2007. In the conference call, Levine said he would expect the transaction to raise earnings per share in the low double-digit percentages. However, CIBC analyst John Calcagnini repeatedly called that estimate too high. >Mentor was asked if it would consider a hostile bid if resistance continues. "We're going to wait for the dust to settle," Levine said on the call. "We know what our options are." > more possible white knights (Merk)